Roivant Sciences Files 8-K: Operations & Financial Update

Ticker: ROIV · Form: 8-K · Filed: 2026-04-02T07:00:32-04:00

Sentiment: neutral

Topics: 8-K, financials, operations

TL;DR

Roivant Sciences dropped an 8-K on 4/2/26 covering financials and Reg FD stuff.

AI Summary

Roivant Sciences Ltd. filed an 8-K on April 2, 2026, reporting on their Results of Operations and Financial Condition, and providing Regulation FD Disclosures. The filing includes financial statements and exhibits, with the primary document being an iXBRL 8-K.

Why It Matters

This 8-K filing provides crucial updates on Roivant Sciences' financial performance and operational status, offering insights for investors and stakeholders.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting operational and financial results, not indicating any immediate or significant new risks.

Key Players & Entities

FAQ

What specific items are covered in Roivant Sciences' 8-K filing dated April 2, 2026?

The filing covers Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits).

What is the SEC accession number for this Roivant Sciences 8-K filing?

The SEC accession number for this filing is 0001140361-26-012885.

When was this 8-K filing accepted by the SEC?

The filing was accepted on April 2, 2026, at 07:00:32.

What is the CIK number for Roivant Sciences Ltd.?

The CIK number for Roivant Sciences Ltd. is 0001635088.

What are the business and mailing addresses listed for Roivant Sciences Ltd.?

Both the business and mailing addresses are listed as 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM SW1H 0DB.

From the Filing

EDGAR Filing Documents for 0001140361-26-012885 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001140361-26-012885 Filing Date 2026-04-02 Accepted 2026-04-02 07:00:32 Documents 12 Period of Report 2026-04-02 Items Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K ef20069685_8k.htm iXBRL 8-K 32486 2 EXHIBIT 99.1 ef20069685_ex99-1.htm EX-99.1 23302 Complete submission text file 0001140361-26-012885.txt 192219 Data Files Seq Description Document Type Size 3 XBRL TAXONOMY EXTENSION SCHEMA roiv-20260402.xsd EX-101.SCH 3862 4 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20260402_lab.xml EX-101.LAB 21966 5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20260402_pre.xml EX-101.PRE 16042 15 EXTRACTED XBRL INSTANCE DOCUMENT ef20069685_8k_htm.xml XML 4208 Mailing Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB Business Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB 441-295-5950 Roivant Sciences Ltd. (Filer) CIK : 0001635088 (see all company filings) EIN. : 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331 Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 26830585 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)

View on Read The Filing